Vitiligo is a chronic autoimmune disease that presents as depigmenting the skin. It affects more than 1.5 million people in the U.S., according to an Incyte press release.
After 52 weeks, phase 3 trials for topical cream Opzelura showed improvements from the baseline in the facial Vitiligo Area Sourcing Index among 50 percent of the study participants.
Opzelura, a JAK inhibitor, is approved for ages 12 and up for nonsegmental vitiligo and mild to moderate eczema.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
